Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 56

Sort by

Sort Order Select

Journal Articles

Hetrombopag Added to Immunosuppressive Therapy in First-Line Treatment of Severe Aplastic Anemia: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial

Blood (2024) 144 (Supplement 1): 304.

https://doi.org/10.1182/blood-2024-206377

Published: 2024

Journal Articles

Post Hoc Analysis of Phase III Gecacitinib Clinical Trial Outcomes: Enhanced Understanding and Implications

Blood (2024) 144 (Supplement 1): 3165.

https://doi.org/10.1182/blood-2024-202790

Published: 2024

Journal Articles

Combining Intensive Immunosuppressive Therapy with Eltrombopag in the Severe Aplastic Anemia: Mild Aggravation of Hepatic Injury

Xiaoyu Chen, Chengtao Qin, Ting Zhang, Yuemin Gong, Yawen Zhang, Guangsheng He, Jianyong Li

Blood (2024) 144 (Supplement 1): 5678.

https://doi.org/10.1182/blood-2024-203363

Published: 2024

Journal Articles

Gene Mutation Profiles of Primary Pure Red Cell Aplasia and Large Granular Lymphocytic Leukemia Associated Pure Red Cell Aplasia

Yawen Zhang, Yuemin Gong, Xiaoqing Liu, Guangsheng He, Lei Fan, Jianyong Li

Blood (2024) 144 (Supplement 1): 5676.

https://doi.org/10.1182/blood-2024-202927

Published: 2024

Journal Articles

Torque Teno Viruses Infection Associated with Suboptimal Hematological Recovery of Severe Aplastic Anemia

Yuemin Gong, Yawen Zhang, Jianyong Li, Guangsheng He, Lei Fan

Blood (2024) 144 (Supplement 1): 2702.

https://doi.org/10.1182/blood-2024-202874

Published: 2024

Journal Articles

Comparisons between Haploidentical Hematopoietic Stem Cell Transplantation and Eltrombopag Adding to Standard Immunosuppression in Patients with Severe Aplastic Anemia

Andie Fu, Mengyuan Li, Yizhou Peng, Bin Xu, Li Li, Jin-song Jia, Yan Yang, Shengyun Lin, Jia Wei, Fankai Meng, Donghua Zhang, Guangsheng He

Blood (2024) 144 (Supplement 1): 3567.

https://doi.org/10.1182/blood-2024-199689

Published: 2024

Journal Articles

Phase III Randomized COMMODORE 2 Trial: 2-Year Efficacy and Safety of Crovalimab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Naive to Complement Inhibition

Alexander Röth, Guangsheng He, Andres Brodsky, Chatree Chai-Adisaksopha, Narcisa Sonia Comia, Anna Gaya, Martin Höglund, Richard J. Kelly, Ahlam Naila Kori, Je-Hwan Lee, Naoshi Obara, Antonio M Risitano, Anita Appius, Leigh Beveridge, Brittany Gentile, Zilu Zhang, Bing Han, Sasha Sreckovic

Blood (2024) 144 (Supplement 1): 2687.

https://doi.org/10.1182/blood-2024-208072

Published: 2024

Journal Articles

The Efficacy of Hetrombopag Combined with Cyclosporine a in Patients with Transfusion-Dependent Non-Severe Aplastic Anemia

Yuemin Gong, Xiaoyu Chen, Yawen Zhang, Guangsheng He, Jianyong Li

Blood (2023) 142 (Supplement 1): 1343.

https://doi.org/10.1182/blood-2023-182723

Published: 2023

Journal Articles

Clinical Features and Outcomes in Large Granular Lymphocyte Leukemia-Associated Pure Red Cell Aplasia with STAT3 Mutation

Xiaoqing Liu, Xiaoyu Chen, Yuemin Gong, Qiqiang Long, Guangsheng He, Jianyong Li

Blood (2023) 142 (Supplement 1): 1353.

https://doi.org/10.1182/blood-2023-186337

Published: 2023

Journal Articles

In Vivo Effects of Porcine and Rabbit Antithymocyte Globulin in Patients with Severe Aplastic Anemia

Yawen Zhang, Yingying Zhang, Anqi Xiong, Yuemin Gong, Xiaoyu Chen, Yu Sun, Guangsheng He, Jianyong Li

Blood (2023) 142 (Supplement 1): 5630.

https://doi.org/10.1182/blood-2023-182856

Published: 2023

Journal Articles

Safety of Crovalimab Versus Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Pooled Results from the Phase III COMMODORE 1, COMMODORE 2, and COMMODORE 3 Studies

Alexander Roeth, Rong FU, Guangsheng He, Hazza A Alzahrani, Sheng-Chieh Chou, Yosr Hicheri, Maciej Kazmierczak, Viviane Lacorte Recova, Michihiro Uchiyama, ANA Maria Vladareanu, Leigh Beveridge, Simon Buatois, Muriel Buri, Dayu Shi, Nadiesh Balachandran, Sasha Srekovic, Phillip Scheinberg

Blood (2023) 142 (Supplement 1): 575.

https://doi.org/10.1182/blood-2023-177618

Published: 2023

Journal Articles

No Benefits from Glucocorticoid Maintenance Therapy in Patients with PNH

Hui Yang, Xiaoyu Chen, Yuemin Gong, Yawen Zhang, Jinge Xu, Dan Xu, Jianyong Li, Guangsheng He

Blood (2023) 142 (Supplement 1): 5638.

https://doi.org/10.1182/blood-2023-189210

Published: 2023

Journal Articles

Cyclophosphamide Combined with Prednisone for Cyclosporine-Refractory/Relapsed Large Granular Lymphocyte Leukemia-Associated Pure Red Cell Aplasia

Xiaoqing Liu, Qiqiang Long, Xi Chen, Chun Qiao, Guangsheng He, Shengyun Lin, Jianyong Li

Blood (2022) 140 (Supplement 1): 2926–2927.

https://doi.org/10.1182/blood-2022-168600

Published: 2022

Journal Articles

Iron Chelation of Hetrombopag in Aplastic Anemia: A Post Hoc Analysis of a Phase II Study

Wenrui Yang, Xin Zhao, Guangsheng He, Hong Chang, Bing Han, Sujun Gao, Shunqing Wang, Tong Chen, Fei Li, Yi Wang, Xiaoyan Ge, Rong Fu, Zheng Ge, Yingmei Li, Hong Liu, Xinjian Liu, Miao Miao, Liansheng Zhang, Fengkui Zhang

Blood (2022) 140 (Supplement 1): 5809–5810.

https://doi.org/10.1182/blood-2022-164560

Published: 2022

Journal Articles

Trial in Progress: An Open-Label, Phase 2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of KP104 in Complement Inhibitor-Naïve Subjects with Paroxysmal Nocturnal Hemoglobinuria

Fengkui Zhang, Bing Han, Guangsheng He, Hu Zhou, Chunrong Wang, Changhe Yue, Jay Ma, Martin Rabe, Helen Fu, Chaomei He, Ping Tsui, Jingtao Wu, Frederick Beddingfield, Wenru Song, Richard Lee

Blood (2022) 140 (Supplement 1): 11459–11460.

https://doi.org/10.1182/blood-2022-159172

Published: 2022

Journal Articles

Prospective Self-Control Analysis of Glucocorticoid Maintenance Therapy for Paroxysmal Nocturnal Hemoglobinuria

Hui Yang, Yuemin Gong, Ruixin Li, Chun Qiao, Run Zhang, Guangsheng He, Jianyong Li

Blood (2022) 140 (Supplement 1): 11455–11456.

https://doi.org/10.1182/blood-2022-166197

Published: 2022

Journal Articles

Prolonged Use of Eltrombopag in Patients with Severe Aplastic Anemia without Complete Response at 6 Months after Immunosuppressive Therapy

Ruixin Li, Qiqiang Long, Yan Yang, Shengyun Lin, Jinsong Jia, Donghua Zhang, Guangsheng He, Jianyong Li

Blood (2022) 140 (Supplement 1): 8650–8651.

https://doi.org/10.1182/blood-2022-165120

Published: 2022

Journal Articles

Intensive Immunosupressive Therapy Combining with Eltrombopag for Adult Chinese Patients with Severe Aplastic Anemia

Ruixin Li, Yuanyuan Jin, Jinsong Jia, Shengyun Lin, Yan Yang, Guangsheng He, Jianyong Li

Blood (2021) 138 (Supplement 1): 2190.

https://doi.org/10.1182/blood-2021-154361

Published: 2021

Journal Articles

Two Currently Recruiting Randomized Phase III Trials: COMMODORE 1 and 2 Evaluating Crovalimab Vs Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria with or without Current Anti-Complement Therapy

Austin G. Kulasekararaj, Antonio Risitano, Alexander Roeth, Guangsheng He, Jeffrey Pu, Lilyan Wright, Anita Appius, Alexandre Sostelly, Sasha Sreckovic, Sven F Stanzel, Talha Munir, Jun-Ichi Nishimura

Blood (2021) 138 (Supplement 1): 4313.

https://doi.org/10.1182/blood-2021-152306

Published: 2021

Journal Articles

Immunosuppressive Therapy in Large Granular Lymphocyte Leukemia-Associated Pure Red Cell Aplasia: Cyclophosphamide Responded Better Than Cyclosporine

Xiaoqing Liu, Ruixin Li, Zhengyuan Liu, Jiongtao Zhou, Lang Cheng, Qiqiang Long, Guangsheng He, Jianyong Li

Blood (2021) 138 (Supplement 1): 1120.

https://doi.org/10.1182/blood-2021-154248

Published: 2021

NARROW

Hetrombopag Added to Immunosuppressive Therapy in First-Line Treatment of Severe Aplastic Anemia: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial

Post Hoc Analysis of Phase III Gecacitinib Clinical Trial Outcomes: Enhanced Understanding and Implications

Combining Intensive Immunosuppressive Therapy with Eltrombopag in the Severe Aplastic Anemia: Mild Aggravation of Hepatic Injury

Gene Mutation Profiles of Primary Pure Red Cell Aplasia and Large Granular Lymphocytic Leukemia Associated Pure Red Cell Aplasia

Torque Teno Viruses Infection Associated with Suboptimal Hematological Recovery of Severe Aplastic Anemia

Comparisons between Haploidentical Hematopoietic Stem Cell Transplantation and Eltrombopag Adding to Standard Immunosuppression in Patients with Severe Aplastic Anemia

Phase III Randomized COMMODORE 2 Trial: 2-Year Efficacy and Safety of Crovalimab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Naive to Complement Inhibition

The Efficacy of Hetrombopag Combined with Cyclosporine a in Patients with Transfusion-Dependent Non-Severe Aplastic Anemia

Clinical Features and Outcomes in Large Granular Lymphocyte Leukemia-Associated Pure Red Cell Aplasia with STAT3 Mutation

In Vivo Effects of Porcine and Rabbit Antithymocyte Globulin in Patients with Severe Aplastic Anemia

Safety of Crovalimab Versus Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Pooled Results from the Phase III COMMODORE 1, COMMODORE 2, and COMMODORE 3 Studies

No Benefits from Glucocorticoid Maintenance Therapy in Patients with PNH

Cyclophosphamide Combined with Prednisone for Cyclosporine-Refractory/Relapsed Large Granular Lymphocyte Leukemia-Associated Pure Red Cell Aplasia

Iron Chelation of Hetrombopag in Aplastic Anemia: A Post Hoc Analysis of a Phase II Study

Trial in Progress: An Open-Label, Phase 2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of KP104 in Complement Inhibitor-Naïve Subjects with Paroxysmal Nocturnal Hemoglobinuria

Prospective Self-Control Analysis of Glucocorticoid Maintenance Therapy for Paroxysmal Nocturnal Hemoglobinuria

Prolonged Use of Eltrombopag in Patients with Severe Aplastic Anemia without Complete Response at 6 Months after Immunosuppressive Therapy

Intensive Immunosupressive Therapy Combining with Eltrombopag for Adult Chinese Patients with Severe Aplastic Anemia

Two Currently Recruiting Randomized Phase III Trials: COMMODORE 1 and 2 Evaluating Crovalimab Vs Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria with or without Current Anti-Complement Therapy

Immunosuppressive Therapy in Large Granular Lymphocyte Leukemia-Associated Pure Red Cell Aplasia: Cyclophosphamide Responded Better Than Cyclosporine

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only